JPWO2022217030A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022217030A5
JPWO2022217030A5 JP2023562191A JP2023562191A JPWO2022217030A5 JP WO2022217030 A5 JPWO2022217030 A5 JP WO2022217030A5 JP 2023562191 A JP2023562191 A JP 2023562191A JP 2023562191 A JP2023562191 A JP 2023562191A JP WO2022217030 A5 JPWO2022217030 A5 JP WO2022217030A5
Authority
JP
Japan
Prior art keywords
cryoprotectant
optionally
dextran
pharmaceutical product
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516110A (ja
JP2024516110A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023979 external-priority patent/WO2022217030A1/en
Publication of JP2024516110A publication Critical patent/JP2024516110A/ja
Publication of JP2024516110A5 publication Critical patent/JP2024516110A5/ja
Publication of JPWO2022217030A5 publication Critical patent/JPWO2022217030A5/ja
Pending legal-status Critical Current

Links

JP2023562191A 2021-04-08 2022-04-08 細菌を含有する医薬組成物 Pending JP2024516110A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172370P 2021-04-08 2021-04-08
US63/172,370 2021-04-08
US202163197000P 2021-06-04 2021-06-04
US63/197,000 2021-06-04
PCT/US2022/023979 WO2022217030A1 (en) 2021-04-08 2022-04-08 Pharmaceutical composition containing bacteria

Publications (3)

Publication Number Publication Date
JP2024516110A JP2024516110A (ja) 2024-04-12
JP2024516110A5 JP2024516110A5 (https=) 2025-04-15
JPWO2022217030A5 true JPWO2022217030A5 (https=) 2025-04-15

Family

ID=81581166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562191A Pending JP2024516110A (ja) 2021-04-08 2022-04-08 細菌を含有する医薬組成物

Country Status (6)

Country Link
US (1) US20250073285A1 (https=)
EP (1) EP4319723A1 (https=)
JP (1) JP2024516110A (https=)
KR (1) KR20240006543A (https=)
TW (1) TW202304415A (https=)
WO (1) WO2022217030A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801578B1 (en) * 2018-06-07 2023-08-30 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
US20070065513A1 (en) 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
WO2010124855A1 (en) * 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
CA2903375C (en) 2013-03-01 2020-11-24 Bpsi Holdings, Llc. Delayed release film coatings containing calcium silicate and substrates coated therewith
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
MA51770A (fr) * 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
EP3749340A1 (en) * 2018-02-06 2020-12-16 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using veillonella bacteria
JP7012840B2 (ja) * 2018-05-31 2022-01-28 ベルテクス株式会社 乳酸菌及びその用途
EP3801578B1 (en) 2018-06-07 2023-08-30 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use
WO2020120714A1 (en) 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
IT201900006056A1 (it) * 2019-04-18 2020-10-18 Probiotical Spa Procedimento per la preparazione di una biomassa di cellule di batteri liofilizzate stabili e determinazione della loro stabilità mediante un metodo citofluorimetrico
JP7797208B2 (ja) * 2019-06-21 2026-01-13 エヴェロ バイオサイエンシズ，インコーポレーテッド プレボテラ（Ｐｒｅｖｏｔｅｌｌａ）を使用してＴＨ２媒介性状態を処置する組成物及び方法
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp

Similar Documents

Publication Publication Date Title
JP3752421B2 (ja) 乳酸菌の安定化のための微細腸溶性コーティング顆粒
EP2605759B1 (en) Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid
JP6695337B2 (ja) エタノールの影響に対する耐性を有する医薬品組成物または栄養機能食品組成物
HUE031603T2 (en) Medicinal or food preparation with extended release characteristics and resistance to ethanol
JP2018518478A (ja) エタノールの影響に対する耐性を有する医薬品組成物または栄養機能食品組成物
KR101686176B1 (ko) 내산성 및 안정성이 향상된 프로바이오틱스 코팅 고체 조성물의 제조 방법
JP5940869B2 (ja) 腸内環境改善有核錠製剤及びハードカプセル製剤
JP5957280B2 (ja) 大腸デリバリーシームレスカプセル製剤及びその製造方法
JPWO2022217030A5 (https=)
KR102777246B1 (ko) 결장 약물 운반 제형
JPWO2021133904A5 (https=)
CN218165648U (zh) 一种保持益生菌活性的制剂
GB2394416A (en) Targeted delivery of microbially encapsulated drugs
EP4518841B1 (en) Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent
US20240189236A1 (en) Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants
JP2024521153A (ja) 改良された剥離コーティングを有する硬質シェルカプセル
EP4493165A1 (en) Pre-functionalized hard shell capsule with accelerated drug release at ph value 5 to 5.5
HK40121160B (en) Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent
WO2023280649A1 (en) Hard shell capsules having improved colon release
de Conto et al. Polysaccharides used for Microencapsulation Processes
JP2024521755A (ja) 胃液の流入を防止する硬質シェルカプセル
KR20220090733A (ko) 칼슘으로 코팅된 유산균 제제 및 이의 제조방법